中国P站

Telehealth; Oncology care; Cancer screening; Preventive healthcare; Access to care; Remote consultation; Digital health; Health equity; Underserved populations; Mobile health technology; Screening outreach; Early detection; Public health intervention; Virtual care delivery; Health system integration

Introduction

Access to preventive cancer screening is a critical determinant of early diagnosis and improved cancer outcomes. However, disparities in access remain a persistent challenge, especially among rural, low-income, and underserved populations. Telehealth, defined as the use of electronic communication technologies to provide healthcare services remotely, has emerged as a powerful tool in oncology to bridge these gaps [1-5]. The integration of telehealth in cancer care not only enables remote clinical assessments but also supports population-based preventive strategies by increasing the reach and efficiency of screening services. In oncology, where timely screening can mean the difference between early-stage intervention and late-stage diagnosis, telehealth plays a pivotal role in improving accessibility, patient compliance, and continuity of care. With increased global digital connectivity and mobile device penetration, telehealth provides a scalable, cost-effective approach to bringing preventive oncology services closer to individuals, regardless of geographic or socioeconomic barriers. This shift aligns with the growing need for healthcare systems to become more inclusive, equitable, and preventive in their approach to cancer management [6-10].

Discussion

The use of telehealth in oncology enhances the entire continuum of preventive cancer care, from patient education and risk assessment to screening reminders and post-screening follow-up. Digital platforms enable individuals to consult healthcare providers remotely, receive guidance on appropriate screening tests based on personal risk factors, and be referred for diagnostics when necessary. In regions where specialized oncologists or cancer screening facilities are limited, teleconsultations can reduce wait times and increase participation in early detection programs. For example, individuals at risk for cervical, breast, colorectal, or lung cancer can engage in virtual consultations, complete risk assessments online, and be directed to appropriate screening services with minimal delay.

Health systems are increasingly using mobile health technology and AI-supported tools to identify high-risk populations and implement targeted outreach programs. These tools support personalized screening schedules and automate appointment reminders, significantly improving patient adherence to preventive protocols. Furthermore, telehealth platforms can be used to deliver culturally tailored education and counseling, which is particularly beneficial in communities with limited health literacy or language barriers. Virtual group sessions and webinars provide an additional means to increase awareness and normalize the importance of routine cancer screening.

Telehealth also supports coordination between different levels of the healthcare system. Primary care providers, community health workers, and oncology specialists can collaborate through digital platforms to ensure continuity of care, particularly in follow-up stages after an initial screening. Integration of electronic health records (EHRs) with telehealth services enhances data sharing, improves documentation, and allows for long-term monitoring of individuals who may need repeat screenings or additional risk evaluation. Additionally, teleradiology and telepathology enable rapid interpretation of diagnostic tests by specialists who may not be locally available, thus expediting the diagnostic process.

Despite its potential, several barriers need to be addressed for telehealth to reach its full capacity in oncology. Limited internet access, lack of digital literacy, concerns over privacy and data security, and resistance to technology use among older populations can hinder telehealth adoption. These challenges are more pronounced in rural and low-resource settings. Therefore, implementation strategies must include infrastructure development, community education, and user-friendly technology interfaces. Policymakers and health authorities must also consider appropriate regulatory frameworks, standardized practices, and reimbursement policies to support the long-term sustainability of telehealth services.

Furthermore, training healthcare providers in telehealth competencies is essential to maintain clinical quality and foster meaningful patient engagement. Empathy, communication, and ethical considerations remain critical even in virtual environments. Collaborative efforts between government bodies, private sectors, and community-based organizations are crucial in promoting equitable access to preventive oncology services through telehealth.

Conclusion

Telehealth is reshaping the landscape of cancer prevention by making screening services more inclusive, accessible, and patient-centered. It offers a practical solution to longstanding challenges in healthcare delivery, particularly for marginalized populations. By overcoming geographical, financial, and systemic barriers, telehealth offers a viable solution to the long-standing disparities in cancer screening and early detection. Its ability to facilitate early intervention, coordinate multidisciplinary care, and support public health outreach makes it an invaluable tool in the oncology field. However, to ensure its effectiveness and sustainability, investments in digital infrastructure, provider training, policy development, and community engagement are imperative. As healthcare systems around the world strive for equity and prevention, telehealth in oncology will remain a cornerstone of modern cancer care strategy, ultimately improving outcomes and saving lives through early detection and proactive management.

References

1. Lynch K (2019). Society 56: 550-554.

, ,

1. Feng J, Wang J, Zhang Y, Zhang Y, Jia L, et al. (2021). Evid Based Complement Alternat Med 2021: 6634309.

, ,

1. Berwick DM (1998). Ann Intern Med US 128: 651-656.

, ,

1. Lin J, Ma H, Li H, Han J, Guo T, et al. (2022). Evid Based Complement Alternat Med 2022: 4624311.

, ,

1. Secretariat MA (2006). Ont Health Technol Assess Ser 6: 1-63.

,

1. Cissen M, Bensdorp A, Cohlen BJ, Repping S, Bruin JPD, et al. (2016). Cochrane Database Syst Rev 2: CD000360.

, ,

1. Veltman-Verhulst SM, Hughes E, Ayeleke RO, Cohlen BJ (2016). Cochrane Database Syst Rev 2: CD001838.

, ,

1. Tokgoz VY, Sukur YE, Ozmen B, Sonmezer M, Berker B, et al (2021). JBRA Assist Reprod 25: 383-389.

, ,

1. Sethi A, Singh N, Patel G (2023). JBRA Assist Reprod 27: 142.

, ,

1. Weiss NS, Kostova E, Nahuis M, Mol BWJ, Veen FVD, et al. (2019). Cochrane Database Syst Rev 1: CD010290.

, ,